Comparative study of predisposition to thrombosis with administration of known systemic hemostatic agents and fibrin monomer in the experiment

Aim. To compare predisposition to thrombosis caused by administration of known systemic hemostatic agents and fibrin monomer under the conditions of normal coagulation versus drug-induced hypocoagulation in the experiment.

Materials and methods. The prothrombotic effect of intravenous (IV) administration of various systemic hemostatic agents was compared in a series of in vivo experiments. These agents included fibrin monomer (FM) (0.25 mg / kg), prothrombin complex concentrate (PCC) (40 IU / kg) or recombinant factor VIIa (rFVIIa) (270 mcg / kg). The studies were conducted under the conditions of hypocoagulation induced by the administration of warfarin (per os at a dose of 0.4–0.5 mg / kg / day for 14 days) or dabigatran etexilate (per os at a single dose of 15–20 mg / kg). Hemostatic system parameters were evaluated using thromboelastometry and calibrated automated thrombography.

Results. It was found that PCC reversed anticoagulant effects and led to an overcompensated increase in the density characteristics of the blood clot along with an excessive increase in thrombin generation in the groups of animals with warfarin-induced coagulopathy. The use of PCC and rFVIIa in the groups of animals with dabigatran-induced hypocoagulation also resulted in an increase in blood thrombogenic properties. In the administration of PCC, it was manifested though an increased D-dimer level and in administration of rFVIIa – through an increase in the clot density characteristics. At the same time, replacement of these hemostatic agents with FM did not affect the hemostatic system parameters.

Conclusion. FM at a dose of 0.25 mg / kg, as opposed to PCC and rFVIIa, is safer in terms of the risk of thrombosis.

1. Мельник А.А. Механизм действия гемостатических лекарственных препаратов. Hовостu медuцuны u фармацuu. 2017;10(622).

2. Rossaint R., Bouillon B., Cerny V., Coats T.J., Duranteau J., Fernández-Mondéjar E. et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit. Care. 2016;20:100. DOI: 10.1186/s13054-016-1265-x.

3. Момот А.П., Вдовин В.М., Шахматов И.И., Толстокоров И.Г., Oрехов Д.А., Шевченко В.O. и др. Системные гемостатические и протромботические эффекты фибринмономера в эксперименте при дозированной травме печени. Сибирский научный медицинский журнал. 2019;39(1):6–12. DOI: 10.15372/SSMJ20190101.

4. Вдовин В.М., Момот А.П., Красюкова В.O., Tолстокоров И.Г., Oрехов Д.А., Шевченко В.O. и др. Системные гемостатические и гемостазиологические эффекты фибрин-мономера при прямом ингибировании тромбина в эксперименте. Российский физиологический журнал. 2019;105(2):207–215. DOI: 10.1134/S0869813919020109.

5. Вдовин В.М., Момот А.П., Oрехов Д.А., Tолстокоров И.Г., Шевченко В.O., Шахматов И.И. и др. Системные гемостатические и гемостазиологические эффекты низкой дозы фибрин-мономера на фоне действия варфарина в эксперименте. Тромбоз, гемостаз и реология. 2019;79(3):16–23. DOI: 10.25555/THR.2019.3.0885.

6. Момот А.П., Цывкина Л.П., Tараненко И.А., Мамаев А.Н., Сердюк Г.В., Шахматов И.И. и др. Современные методы распознавания состояния тромботической готовности. Барнаул: Алтайский государственный университет, 2011:138.

7. Момот А.П., Шахматов И.И., Ломаев И.С., Tерехов С.С. Способ промышленного получения фибрин-мономера из плазмы крови. Патент РФ № 2522237. 10.07.2014. Бюл. № 19.

8. Гуськова T.А. Доклиническое токсикологическое изучение лекарственных средств как гарантия безопасности проведения их клинических исследований. Токсикологический вестник. 2010;104(5):2–5.

9. Ryn J., Stangier J., Haertter S., Liesenfeld K.-H., Wienen W., Feuring M. et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost. 2010;103(6):1116–1127. DOI: 10.1160/TH09-11-0758.

10. Bavalia R., Abdoellakhan R., Brinkman H.J.M., Brekelmans M.P.A., Hamulyák E.N., Zuurveld M. et al. Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate. Res. Pract. Thromb. Haemost. 2020;4(4):569–581. DOI: 10.1002/rth2.12336.

11. Зозуля Н.И., Кумскова М.А., Полянская T.Ю., Свирин П.В. Клинические рекомендации по диагностике и лечению гемофилии. НГO, 2018:34.

12. Папаян Л.П., Головина O.Г., Чечеткин А.В., Бессмельцев С.С., Капустин С.И., Каргин В.Д. и др. Алгоритм диагностики гемостаза и мониторинг антитромботической терапии. Методические рекомендации. СПб: Российский научно-исследовательский институт гематологии и трансфузиологии, 2016:18.

13. Вдовин В.М., Момот А.П., Oрехов Д.А., Бобров И.П., Момот Д.А., Шахматов И.И. и др. Влияние экзогенного фибрин-мономера на гемостатический потенциал и образование фибрина в области дозированной травмы печени в эксперименте. Российский физиологический журнал им. И.М. Сеченова. 2020;106(9):1132–1143. DOI: 10.31857/S0869813920070092.

14. Girolami A., Marinis G.B., Bonamigo E., Lombardi A.M. Recombinant FVIIa concentrate-associated thrombotic events in congenital bleeding disorders other than hemophilias. Hematology. 2012;17(6):346–349. DOI: 10.1179/1607845412Y.0000000027.

15. Pichon N., Bellec F., Sekkal S., Marsaud J.P., Laskar M., François B. et al. Fatal thrombotic event after infusion of recombinant activated factor VII after cardiac surgery. J. Thorac. Cardiovasc. Surg. 2008;136(1):220–221. DOI: 10.1016/j.jtcvs.2007.10.084.

16. Hajj-Chahine J., Jayle C., Tomasi J., Houmaida H., Corbi P. Acute aortic valve thrombosis secondary to recombinant factor VIIa. Ann. Thorac. Surg. 2012;93:999. DOI: 10.1016/j.athoracsur.2011.08.050.

17. Levi M., Levy J.H., Andersen H.F., Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N. Engl. J. Med. 2010;363(19):1791–1800. DOI: 10.1056/NEJMoa1006221.

18. Yates S.G., Sarode R. New strategies for effective treatment of vitamin K antagonist-associated bleeding. J. Thromb. Haemost. 2015;13(Suppl.1):S180–S186. DOI: 10.1111/jth.12970.

19. Köhler M. Thrombogenicity of prothrombin complex concentrates. Thromb. Res. 1999;95(4Suppl.1):S13–S17. DOI: 10.1016/s0049-3848(99)00079-1.

20. Ehrlich H.J., Henzl M.J., Gomperts E.D. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia. 2002;8(2):83–90. DOI: 10.1046/j.1365-2516.2002.00532.x.

21. Goldhammer J.E., Bakowitz M.J., Milas B.L., Patel P.A. Intracardiac thrombosis after emergent prothrombin complex concentrate administration for warfarin reversal. Anesthesiology. 2015;123(2):458. DOI: 10.1097/ALN.0000000000000464.

22. Brinkman H.J.M. Prothrombin complex concentrate, a general antidote for oral anticoagulation. In the book: Basaran O. Anticoagulation Therapy, 2016. Chapter 5:79–109. DOI: 10.5772/64304.

23. Gavva C., Reddy M., Sarode R. Four-factor prothrombin complex concentrates effectiveness in the reversal of anticoagulation. International Journal of Clinical Transfusion Medicine. 2017;2017(5):39–47. DOI: 10.2147/IJCTM.S114736.

24. Rajpurkar M., Croteau S.E., Boggio L., Cooper D.L. Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC). J. Blood Med. 2019;10:335–340. DOI: 10.2147/JBM.S219573.